|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
1/23/2013 7:26:13 AM
Pfizer Inc. (PFE) and Bristol-Myers Squibb Co. (BMY)’s Eliquis won the backing of the U.K.’s health-cost regulator for people with an irregular heartbeat, putting the drug in line to be the third new treatment recommended for such patients in the past year. The National Institute for Health and Clinical Excellence issued draft guidance recommending the blood thinner to prevent strokes in patients with atrial fibrillation, the agency said today in an e-mailed statement. NICE asked patients and doctors to talk before using Eliquis about whether to choose one of the other two new drugs or the older medicine warfarin instead. Eliquis will compete with Bayer AG (BAYN) and Johnson & Johnson (JNJ)’s Xarelto and Boehringer Ingelheim GmbH’s Pradaxa to replace warfarin, a decades-old medicine that had previously been the standard of care for people with an erratic heartbeat. Both of the other drugs won a recommendation from NICE last year. “The appraisal committee heard from patient experts that warfarin can have a greater impact on a person’s quality of life than atrial fibrillation itself,” Carole Longson, director of NICE’s Health Technology Evaluation Centre, said in the statement, citing the older drug’s interactions with food, alcohol and other medicines, and the regular monitoring it requires. NICE, which advises the state-run National Health Service on getting medical value for its money, said it will probably issue final guidance on Eliquis, also known as apixaban, in February. The agency recommended the pill in January 2012 for people who have undergone hip or knee replacement surgery.
|
|
|
|
|
|
|
|
|
|
|